US 8,076,316 B2 · Steroid compounds and formulations

Abstract

The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.

Claims7

Dependent claims

A group 9 compound having the structure

Dependencies are inferred from the claim text.

Facts

Application

12/957,661Filed 1 Dec 2010 · continuation

Priority

16 Nov 1999

Published

US 2011/0098260 A128 Apr 2011

Granted

13 Dec 2011

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

A61K 31/568
Not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol: substituted in positions 10 and 13 by a chain having at least one…
A61K 31/565
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids: not substituted in position 17 beta by a…
A61K 31/567
Not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol: substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 31/5685
Substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone: having an oxo group in…

Family

Application60/166,116Us provisional application · filed 16 Nov 1999

Application09/675,323Parent of this continuation · filed 28 Sep 2000

Application11/835,397Parent of this continuation · filed 7 Aug 2007

US 2011/0098260 A1Pre-grant publication · published 28 Apr 2011

US 7,863,261 B2Parent of this continuation

US 2008/0176823 A1Published application

US 8,076,316 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

12/957,661Filed 1 Dec 2010 · continuation

Priority

16 Nov 1999

Published

US 2011/0098260 A128 Apr 2011

Granted

13 Dec 2011

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

A61K 31/568
Not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol: substituted in positions 10 and 13 by a chain having at least one…
A61K 31/565
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids: not substituted in position 17 beta by a…
A61K 31/567
Not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol: substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 31/5685
Substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone: having an oxo group in…

Family

Application60/166,116Us provisional application · filed 16 Nov 1999

Application09/675,323Parent of this continuation · filed 28 Sep 2000

Application11/835,397Parent of this continuation · filed 7 Aug 2007

US 2011/0098260 A1Pre-grant publication · published 28 Apr 2011

US 7,863,261 B2Parent of this continuation

US 2008/0176823 A1Published application

US 8,076,316 B2This patent

From the US filing history. Foreign family members aren’t listed.

Steroid compounds and formulations

Life of this patent

Abstract

Claims7

Steroid compounds and formulations

Life of this patent

Abstract

Claims7